Shanghai Zhongkexin Life Biotechnology

About Shanghai Zhongkexin Life Biotechnology

Shanghai Zhongkexin Life Biotechnology Co., Ltd. (APTBIO) is a life sciences technology service company rooted in mass spectrometry and multi-omics. Established in July 2004, the firm originated as the external service department of the Protein Group Research and Analysis Center at the Shanghai Institute of Life Sciences, a part of the Chinese Academy of Sciences (CAS). This makes it one of the earliest domestic organizations to provide proteomics technology services. The company was founded by Ms. Chen Wei, who continues to lead the company.

The company's business is structured around two main segments: tech-bio services and CRO services for biopharmaceuticals and consumer healthcare. APTBIO serves a diverse client base that includes over 1,500 research institutes and universities, more than 1,000 hospitals, and over 2,000 biopharmaceutical companies. Revenue is generated by providing comprehensive solutions across the life sciences value chain. The business model integrates multi-omics big data applications for precision discovery, diagnostics, and treatment. The company operates on a global scale, with a significant presence in China, including its Shanghai headquarters and centers in Yiwu and Taizhou, and has expanded its sales network to cities like Beijing, Guangzhou, and Tianjin.

APTBIO has developed four major technology platforms: a large-cohort multi-omics research platform, a biopharmaceutical preclinical CMC research and analysis platform, a clinical mass spectrometry and companion diagnostics platform, and an AI big data algorithm platform. Its service offerings are extensive, featuring proteomics solutions like in-depth protein group analysis and post-translational modification analysis, as well as a metabolomics product matrix. The company has assisted in over 300 successful IND applications for biologic drugs and holds certifications including CMA, CNAS, and ISO9001. Significant milestones include completing a Series B financing round in August 2022 and a Series C round in April 2024, which will support the development of innovative products and global market expansion.